Aleglitazar significantly increased ABCA1 expression in primary human hepatocytes at all tested concentrations. In baby hamster kidney cells expressing human PPARα and a luciferase reporter, Aleglitazar yielded a half-maximal activation value of 5 nm. In primary mouse cortical neuronal cultures subjected to oxygen–glucose deprivation, Aleglitazar pretreatment protected against cell death compared with vehicle treatment, as quantified by LDH release. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Aleglitazar increases ABCA1 expression in primary human hepatocytes
Cell-based study · Primary human hepatocytes; five replicates of each treatment concentration [1]
Primary human hepatocytes were incubated with Aleglitazar at 0.013 µM, 0.064 µM or 0.32 µM for 6 hours. Aleglitazar significantly increased ABCA1 expression at all concentrations.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.013 µM, 0.064 µM or 0.32 µM
- Exposure duration
- 6 hours
- Method
- incubated
- Vehicle
- 0.1% dimethyl sulfoxide
Methods and source locations
Compound reported in the paper: Aleglitazar
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Cell culture (S1, S2); Methods > Gene-expression microarray analysis (S12); Results > Lipid metabolic pathways (S63)
ABCA1 expression: ABCA1 expression; comparator: vehicle control — Results > Lipid metabolic pathways (S63)
Aleglitazar activates human PPARα in a reporter assay
Cell-based study · Baby hamster kidney cells (BHK21); human PPARα (amino acids 167–469); pFR-Luc luciferase reporter plasmid [2]
Baby hamster kidney cells expressing human PPARα and a luciferase reporter were incubated with Aleglitazar for 24 h. The half-maximal activation value was 5 nm.
Literature-Reported Treatment Conditions
- Exposure duration
- 24 h incubation in the presence of ligand
- Method
- medium containing the test or reference compound
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: dose. Removed after verification: value.
Methods and source locations
Compound reported in the paper: Aleglitazar
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effects on PPAR transcriptional activity (S1, S5); Experimental Section (S45); Experimental Section > Transactivation assay (S48, S50, S51, S53, S54, S57, S59)
PPARα; receptor transcriptional activity: PPARα; receptor transcriptional activity; comparator: cells incubated at low, non-activating concentrations of the test compound — Results > Effects on PPAR transcriptional activity (S1, S5); Experimental Section > Transactivation assay (S59)
Aleglitazar protects cortical neurons during oxygen–glucose deprivation
Cell-based study · Primary neuronal cultures of mouse cerebral cortex; fetal C57BL/6N mice (E15); N = 5 independent cultures per condition. [3]
Primary mouse cerebral cortical neuronal cultures were pretreated with Aleglitazar at 125 μM for 24 h before 180 min oxygen–glucose deprivation. Within the deprivation condition, Aleglitazar protected against cell death compared with vehicle treatment, as quantified by LDH release.
Literature-Reported Treatment Conditions
- Treatment concentration
- 125 μM
- Exposure duration
- 24 h prior to OGD; 180 min OGD
- Method
- Neuronal cultures were pretreated with aleglitazar
- Vehicle
- 0.25% DMSO in culture medium
- Co-treatment
- Other interventions in this design: oxygen–glucose deprivation (OGD). Compound effect isolated by the comparison: the effect of treatment with aleglitazar within the OGD condition.
Methods and source locations
Compound reported in the paper: Aleglitazar
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Cell culture experiments (S1, S9, S10); Methods > Induction of cerebral ischemia (S74, S76, S77); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S117, S118, S119)
lactate dehydrogenase (LDH) release into the cell culture medium 24 h after OGD: lactate dehydrogenase (LDH) release into the cell culture medium 24 h after OGD; comparator: Vehicle-treated neurons; MK-801 (10 μm) served as a positive control. — Methods > Induction of cerebral ischemia (S74); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S118)